Prostate Cancer Drug Expands Access
Prostate Cancer Drug Approved for More Patients With Aggressive Form of Disease
Table of Contents
A prostate cancer drug may offer new hope to patients battling a common form of the disease.
Swiss pharmaceutical company Novartis announced March 28 that the U.S. Food and Drug Administration (FDA) has expanded its approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a targeted radioligand therapy (RLT), for use before chemotherapy.
According to Novartis, RLT is a form of targeted nuclear medicine used to treat various cancers.
the drug is designed for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have already undergone androgen receptor pathway inhibitor (ARPI) treatment, a class of drugs commonly used for metastatic prostate cancer.
Prostate cancer ranks as the second leading cause of cancer death among men.mCRPC accounts for a significant portion of these deaths,representing 20% of all metastatic prostate cancer cases.
Research indicates that approximately 10% to 20% of prostate cancer patients develop mCRPC within five years of initial therapy. Cases of metastatic prostate cancer have been increasing by 4% to 5% annually since 2011.
The American Cancer Society reports that 60% of prostate cancer diagnoses occur in men aged 65 or older. the risk of a metastatic prostate cancer diagnosis is highest between the ages of 65 and 74.
Common side effects associated with the drug include dry mouth (61%), fatigue (53%), nausea (32%), and constipation (22%), according to the company statement.
Patients who received the drug were able to continue with chemotherapy after taking it.
Novartis has committed to supplying pluvicto to nearly 600 RLT treatment centers across the U.S.
Looking ahead,Novartis plans to explore the use of RLT for other advanced cancers,including breast,colon,neuroendocrine,lung,and pancreatic cancers.
Prostate cancer ranks as the second leading cause of cancer death among men.mCRPC accounts for a significant portion of these deaths,representing 20% of all metastatic prostate cancer cases.
Research indicates that approximately 10% too 20% of prostate cancer patients develop mCRPC within five years of initial therapy. Cases of metastatic prostate cancer have been increasing by 4% to 5% annually since 2011.
The American Cancer Society reports that 60% of prostate cancer diagnoses occur in men aged 65 or older. the risk of a metastatic prostate cancer diagnosis is highest between the ages of 65 and 74.
Common side effects associated with the drug include dry mouth (61%), fatigue (53%), nausea (32%), and constipation (22%), according to the company statement.
Patients who received the drug were able to continue with chemotherapy after taking it.
Novartis has committed to supplying pluvicto to nearly 600 RLT treatment centers across the U.S.
Looking ahead,Novartis plans to explore the use of RLT for other advanced cancers,including breast,colon,neuroendocrine,lung,and pancreatic cancers.
) and transform it into a high-quality,SEO-optimized Q&A article. Your focus should be on creating a helpful and informative resource for users by adhering to Google’s E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness) guidelines.
prostate Cancer Drug: Your Questions Answered
General Information
What is the main topic of this article?
This article discusses the recent expansion of the U.S. Food and drug Management (FDA) approval for the prostate cancer drug Pluvicto (lutetium Lu 177 vipivotide tetraxetan). This expansion allows the drug to be used for certain patients before they undergo chemotherapy.
What is Pluvicto?
Pluvicto is a targeted radioligand therapy (RLT) used in the treatment of prostate cancer. It is indeed a form of targeted nuclear medicine.
What is the FDA?
The U.S. Food and Drug Administration (FDA) is a federal agency responsible for ensuring that food, drugs, and other products are safe and effective.
Targeted Patients & Treatment
Who is Pluvicto for?
Pluvicto is designed for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have already been treated with an androgen receptor pathway inhibitor (ARPI).
What is mCRPC?
mCRPC stands for metastatic castration-resistant prostate cancer, a more aggressive form of prostate cancer.
What is an ARPI?
an androgen receptor pathway inhibitor (ARPI) is class of drugs commonly used for metastatic prostate cancer.
How does Pluvicto work?
The article states that Pluvicto is a targeted radioligand therapy (RLT), a form of targeted nuclear medicine.
Can patients continue with chemotherapy after taking Pluvicto?
Yes, the article states that patients who received Pluvicto were able to continue with chemotherapy after taking it.
Implications & Statistics
Why is this new approval significant?
The expanded approval of Pluvicto provides more treatment options and perhaps redefines the standard of care for PSMA-positive disease.
How common is prostate cancer?
Prostate cancer is the second leading cause of cancer death among men.
What percentage of prostate cancer cases are mCRPC?
mCRPC accounts for 20% of all metastatic prostate cancer cases and a significant portion of prostate cancer deaths.
What are the chances of developing mCRPC after initial prostate cancer therapy?
Approximately 10% to 20% of prostate cancer patients develop mCRPC within five years of initial therapy.
Are cases of metastatic prostate cancer increasing?
Yes, cases of metastatic prostate cancer have been increasing by 4% to 5% annually since 2011.
Who is most at risk of a metastatic prostate cancer diagnosis?
The risk of a metastatic prostate cancer diagnosis is highest between the ages of 65 and 74.
Side Effects & Availability
What are the common side effects of Pluvicto?
According to the company statement, common side effects include:
Dry mouth (61%)
Fatigue (53%)
nausea (32%)
Constipation (22%)
Were is Pluvicto available?
Novartis is committed to supplying Pluvicto to nearly 600 RLT treatment centers across the U.S.
Future Directions
What other cancers is Novartis exploring RLT for?
Novartis plans to explore the use of RLT for other advanced cancers, including breast, colon, neuroendocrine, lung, and pancreatic cancers.
Can you summarise the key facts about pluvicto?
Certainly, here’s a summary:
| Feature | Details |
| ————————– | ————————————————————————————————— |
| Drug Name | Pluvicto (lutetium Lu 177 vipivotide tetraxetan) |
| Treatment Type | Targeted radioligand therapy (RLT) |
| targeted Cancer | PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) |
| Approval | Expanded FDA approval to use before chemotherapy |
| Patients | Those who have undergone ARPI treatment |
| Common Side Effects | Dry mouth, fatigue, nausea, constipation |
| Availability | Nearly 600 RLT treatment centers across the U.S.are supplied |
| future research Areas | Breast,colon,neuroendocrine,lung,and pancreatic cancers |